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Antibiotic-loaded bone cements (ALBCs) may offer early protection against the 
formation of bacterial biofilm after joint replacement. Use in hip replacement is 
widely accepted, but there is a lack of evidence in total knee replacement (TKR). 
ALBCs are more costly than plain cement, and there are concerns regarding 
mechanically stability and increased antibiotic resistance. The objective of this 
study is to evaluate the use of ALBC in a large population of TKR patients in 
order to give a recommendation about its use based on a risk-benefit profile.  
 
Patients and Methods: 
Data from the National Joint Registry (NJR) of England and Wales was obtained 
for all primary cemented TKRs between March 2003 and July 2016. Patient, 
implant and surgical variables were analysed. Cox proportional hazards models 
were used to assess the influence of ALBC on risk of revision.  Body mass index 
(BMI) data was available in a subset of patients.  
 
Results:  
Of 731,214 TKRs, 15,295 (2.1%) were implanted with plain and 715,919 
(97.9%) with ALBC.  There were 13,391 revisions; 2391 were performed for 
infection. After adjusting for other variables, ALBC had a significantly lower risk 
of revision for any cause (Hazard Ratio [HR] 0.85, 95% Confidence Intervals [CIs] 
0.77-0.93, p<0.01).  ALBC was associated with a lower risk of revision for all 
aseptic causes (HR 0.85, 0.77-0.95, p<0.01) and revisions for infection (HR 0.84, 
0.67-1.01, p=0.06).  The results were similar when BMI was added into the 
model (432,003 TKRs, all cause revision HR 0.76, 0.65-0.89, p<0.01, aseptic 
revisions HR 0.81, 0.67-0.98, p=0.03, revision for infection HR 0.65, 0.49-0.87, 
p<0.01).  
 
Prosthesis survival at 10 years for TKRs implanted with ALBC was 96.3% [95% 
CIs 96.3-96.4] compared with 95.5% [95.0-95.9] in those implanted with plain 
cement.  On a population level, where 100,000 TKRs are performed annually, this 
is equivalent to 870 fewer revisions at 10 years if ALBC was used.  
 
Conclusions:  
After adjusting for a range of variables, ALBC was associated with a significantly 
lower risk of revision.  Using ALBC does not increase mid-term implant failure 
rates.  Surgeons using plain cement for primary TKRs should consider changing 
to ALBC in order to reduce overall revision risk. 
 
Take home message: 
 ALBC was associated with a significantly lower risk of revision following 
primary TKR 
 The risk reduction in this analysis would result in 8 fewer revisions at 10 
years per 1000 TKRs if ALBC was used rather than plain cement 
 Concerns regarding mechanical instability and antibiotic resistance resulting 
in earlier implant failure when using ALBC are unfounded  
 
Introduction: 
Prosthetic infection after total knee replacement (TKR) is a rare but potentially 
debilitating surgical complication. Its rate has been estimated to be between 1% 
and 2% 1-3.  Biofilm protects infecting organisms against the host immune system 
and systemic antibiotics 4,5, and patients with infected TKRs frequently require 
revision surgery 6, which in turn leads to poorer patient outcome, longer 
hospitalization and significantly increased cost 2,7.  
 
Adding antibiotics to the cement used in prosthetic joint arthroplasty has been 
advocated for many years as a means of reducing the risk of infection as well as 
in the treatment of infected prostheses 8-12. While the efficacy of antibiotic-
loaded bone cement (ALBC) has been demonstrated in revision surgery for both 
treating prosthetic infection and as prophylaxis 10,11,13, the evidence of its efficacy 
in primary prophylaxis lacks clarity 7,8,14, and has led to different practices 
globally 15. 
 
There are also concerns that adding antibiotics to bone cement can adversely 
affect its mechanical properties 16-19 which would effect revision rates.  Some 
authors also believe this can potentially lead to the development of resistant 
organisms that may complicate infection management should the prosthetic 
joint become infected 4,20-23 (although one large study has recently shown local 
antibiotics in cement does not drive resistant infections 24). Moreover, there are 
reports of bone cellular 25,26 and renal toxicity 27-29. These concerns and 
uncertainties challenge the practice of routinely adding antibiotics to the cement 
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in primary TKR without having strong evidence of its efficacy in reducing the 
risk of infection.  
 
In this study we sought to evaluate the hypothesis that ALBC reduces the risk of 
revision following primary TKR.  National Joint Registry (NJR) data were 
analysed to compare the revision rate of primary TKRs performed for 
osteoarthritis using ALBC versus plain cement, in order to provide informed 
recommendations about its efficacy and the risk-benefit ratio.  
 
Methods: 
A proposal was submitted to the research committee of the National Joint 
Registry for England, Wales, Northern Ireland and the Isle of Man in 2016.  
Approval and data access was granted in February 2017.  Data were obtained for 
all primary cemented TKRs recorded on the NJR dataset between 2003 and 2016.  
Knee replacements that were not fully cemented, unicondylar knee replacements 
and revision procedures were excluded.  Patient, implant and surgical variables 
collected by the NJR were provided.   
 
A retrospective observational registry study was carried out.  The following 
endpoints (as recorded on the NJR minimum dataset form) were of interest: 
revision for infection, revision for a cause other than infection, and revision for 
any cause. The use of ALBC was compared with plain bone cement. For each 
endpoint, log rank tests and Cox proportional hazards models were performed to 
compare the groups, both unadjusted for cement variables, and adjusted by 
stratification for patient (gender, patient age group, ASA Grade, BMI where 
available and indication), surgical (approach, surgeon grade, 
thromoprophylaxis) and implant (constraint, bearing, patella) characteristics. 
The influence of timing of surgery (i.e. year of operation) was also explored in 
order to assess the influence of time dependent unknown variables (for e.g. 
different generations of cementation techniques). Body mass index (BMI) data 
was not universally collected in the earlier years of the registry, so this data was 
only available in a subset of patients.  Data on some factors that may influence 
risk of infection, such as immunosuppressing conditions and medications, and 
smoking, are not collected by the NJR and were therefore unavailable for this 
analysis. 
 
The statistical models were tested to ensure the proportional hazards 
assumption was not violated for any of the endpoints (p < 0.05).  For estimation 
of the average hazard ratio a weighted Cox regression was performed to 
calculate an unbiased estimate. Final models were identified by stepwise 
selection and subjected to robustness checks (including constant proportionality 
over time).  Stratified Cox proportional hazard model was considered to account 
for year of operations. 
 
The analysis was performed on the entire dataset (excluding BMI data) and 
repeated for episodes with a valid BMI (range of 15≤ BMI ≤ 50).  Frequency and 
percentages were used to summarise categorical data while mean and standard 
deviation were used for continuous variables. 
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The dataset contained 731,214 records. Figures 1 and 2 depict the distribution of 
the number of patients according to the type of cement used, the surgical 
outcome (revision or no revision), and whether infection was recorded as the 
cause for revision. The data was analysed in three ways depending on whether 
the revised procedure was due to infection or not. In all the analyses, the event 
was defined as “revision” and censoring was defined when there was no revision 
procedure as of 31st July 2016.  
 
Table 3 summarises the distribution of patients across all variables in the dataset 
before and after deleting records with missing BMI data.  The American society 
of anesthesiologist’s grade (ASA) variable was recoded into three categories 
(grade 1, grade 2 and grade ≥ 3). Similarly, age was also recoded into 4 
categories using quartiles as cut-points. 
 
Five-year and 10-year survival rates were calculated, with 95% confidence 









Analyses of all patients (excluding BMI data) 
 
Survival curves comparing TKRs performed using ALBC and plain cement show a 
lower revision rates at two years following surgery in the ALBC group (for the 
endpoints: all cause revision, revision for infection, revision for aseptic causes), 
although the statistical significance was marginal where infection was cited as 
the cause of revision (p=0.06) (Figure 3). 
 
Table 2 presents the univariable analysis.  The following factors were 
independently associated with a significantly increased risk of revision: male sex, 
younger age, lower ASA, indications other than osteoarthritis, patella 
unresurfaced, employing posterior stabilised components and mobile bearings, 
the use of low viscosity and plain (non-antibiotic loaded) cement, and when a 
factor Xa inhibitor was used for venous thromboembolic (VTE) prophylaxis.  
There was no evidence of significant association between the hazard of revision 
and other types of VTE prophylaxis used.  Figure 4 shows that changes in rates of 
revision (hazard ratio) did not vary in a linear manner over time, irrespective of 
indication.  Hazards of revision between the two groups varied across the 
operation years. In general, plain cement had higher hazard of revision than 
ALBC, particularly after 2007.   
 
Table 3 presents multivariable analyses for the association between hazard of 
revision and ALBC status while adjusting for other important factors. In all the 
analyses, the hazard of revision was about 15% less likely for ALBC than plain 
cement after adjusting for other factors including the year of operation.  
 
Analyses of episodes with BMI data  
 
There were 432003 records with BMI data. The Kaplan-Meier curves show 
similar pattern to the analysis with all patients. ALBC had a lower risk of revision 
than plain cement (Figure 5). 
 
Table 4 shows similar results as the analyses of all patients presented in Table 2.  
The following factors were independently associated with a significantly 
increased risk of revision: male sex, younger age, lower ASA, higher BMI, patella 
unresurfaced, employing posterior stabilised components and mobile bearings, 
the use of plain (non-antibiotic loaded) cement, and when a factor Xa inhibitor 
was used for venous thromboembolic (VTE) prophylaxis.  Cement viscosity and 
indication were not associated with revision risk.  
 
Multivariable analysis of the data excluding patients with missing BMI data are 
presented in Table 5.  There is significant association between the hazard of 
revision and ALBC usage. ALBC has about 15% less chance of revision than non-
ALBC, which is similar to the results from the analysis of all patients without 




TKRs implanted with ALBC had a 5-year revision rate of 2.34% (95% CIs 2.30 to 
2.39) and a 10-year rate of 3.66% (3.59 to 3.75) compared with 3.02% (2.72 to 
3.34) and 4.53% (4.10 to 4.99) when plain cement was employed, after adjusting 
for patient and surgical variables.  This equates to an absolute 10-year revision 
risk reduction of 0.87% and a relative risk reduction of 19.2% when ALBC was 
used. The number of patients needed to treat in one year with ALBC to prevent 
one revision is 115.  On a population level, where 100,000 TKRs are performed 
annually, this is equivalent to 870 fewer revisions at 10 years if ALBC was used.  
 
Discussion: 
This retrospective cohort study provides the largest analysis of ALBC in primary 
knee replacement patients.  All cause revision, revision for aseptic causes and 
revision where infection was cited as a cause were all significantly lower in the 
ALBC group compared with plain cement.  Crucially, revision risk for aseptic 
causes was significantly lower when ALBC was used.  Concerns regarding greater 
mechanical instability with the use of ALBC are therefore unfounded in this 
population-based mid-term study.  
 
However, there are limitations.  Data on proven risk factors for periprosthetic 
joint infection, such as diabetes, smoking and length of surgery 30 were 
unavailable in this study.  ASA grade, whilst crude, was therefore used as a 
surrogate for comorbidity in statistical models.  BMI (which is known to 
influence risk of infection) data is incomplete within the NJR, although rates of 
collection have improved in recent years.  Despite this, our analyses 
demonstrated little difference between the cohort with BMI data and the full 
dataset, when BMI was excluded from the statistical models – ALBC was 
associated with a significant reduction in revisions, irrespective of BMI. 
 
Registries rely on data collection at time of surgery, resulting in some 
inaccuracies in stated reason for revision.  For example, revisions apportioned to 
aseptic loosening may ultimately be driven by low-grade infection. As linked 
microbiological data is unavailable, registry analyses are likely to under report 
infection as a cause of revision.  Moreover, the NJR does not record any 
information on superficial infections that are treated conservatively and (in the 
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time period of this study) did not record cases of infection where the treatment 
was a debridement, antibiotics and implant retention (DAIR).  However, there 
would be no logical reason why the use of one type of cement may be more 
associated with registry process issues than the comparator.  
 
While we were able to identify an association between ALBC and lower infection 
risk, we lacked detailed information on the type and dosage of the antibiotics 
added to the cement, antibiotic prophylaxis used and treatment duration, and 
could not, therefore, produce any useful information on whether certain 
antibiotics are more effective than others. Furthermore, we have no data on 
antimicrobial resistance profiles in those patients who were revised for infection 
following original implantation with ALBC. 
 
Finally, the proportion of knee replacements implanted using plain cement in 
this study was only 2%, and most were implanted in the earlier years of the 
registry.  Nevertheless, this still accounts for over 15,000 cases and differences in 
revision rates between cement types were significant despite this relative 
mismatched group sizes.  
 
Prosthetic joint infection is a serious complication following TKA and frequently 
requires revision surgery and leads to poor patient outcome and increased cost 
2,7. Antibiotic-loaded bone cement (ALBC) has been used for prophylaxis 
purposes in primary and revision TKA and also as part of the treatment in 
revision surgery for infected TKA 8-11. It is the most frequently used local 
antibiotic delivery system in joint arthroplasty 31. Acting as a carrier for topical 
delivery of antibiotics, ALBC is thought to reduce the risk of prosthetic infection 
not addressed by systemic antibiotics due to impaired blood supply, and 
therefore low local antibiotic concentrations at the surgical site in the immediate 
postoperative period 14,32.  
 
There is strong evidence of ALBC’s efficacy in treating prosthetic TKA infection 
and as a means of prophylaxis in revision knee surgery. However, its efficacy in 
providing prophylaxis in primary TKA has been a matter of debate. In fact, the 
current evidence is so conflicting that while in some studies ALBC was found to 
reduce the risk of primary TKA infection 13,14,33-40, other studies have shown no 
difference 41-50 or even increased risk of primary TKA infection because of ALBC 
51,52. We are aware of four recent joint replacement registry-based studies that 
examined this subject. Namba et al in their study of an American total joint 
registry identified the use of ALBC in primary TKA as a risk factor for causing 
deep surgical site infection, but at the same time the authors found that adding 
antibiotics to the irrigation solution was protective against deep surgical site 
infection 52. Tayton et al also found ALBC increased the risk of revision for 
infection at 6 months in their review of over 60,000 primary knee replacements 
on the New Zealand joint registry 51. The use of laminar flow and surgical 
helmuts was also associated with greater infection risk.  However, a significant 
limitation to their study was that they did not take into account revisions 
performed after 1 year from the primary operation 51. In both the American and 
New Zealand registry studies the authors proposed an explanation for this: the 
observed paradoxical increase in the rate of infection with the use of ALBC could 
be a result of selection bias, as ALBC was not routinely used in their countries 
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when plain cement was used in primary TKR, and this increased to 2.1x in 
revision TKR 13. Bohm et al analysed the Canadian joint replacement registry 
comparing the revision rates (at 2 year follow up) of primary TKR performed 
using ALBC and plain cement and found no statistically significant difference in 
the rate of revision for all causes. Interestingly a statistically significant doubling 
of the rate of revision for aseptic loosening was found in the plain cement group 
44. However, limitations included selection bias (as ALBC may have been used in 
higher risk patients), and inclusion bias (infections treated with washout and 
implant retention were not included) 44. In their systematic review and meta-
analysis of randomized controlled trials that investigated the efficacy of ALBC in 
reducing infection in primary TKA and THA, Wang et al concluded that compared 
to plain bone cement and the use of systemic antibiotics alone, ALBC effectively 
reduced the rate of deep wound infection in THA and TKA patients 14. In the UK, 
ALBC is routinely used in primary TKA, and we found that it was associated with 
an overall 15% reduction in the rate of revision for all causes in primary TKA, 
although the statistical significance was only marginal when we used the 
revision for infection as the endpoint (p=0.06). This decrease in the rate of 
revision for all causes, more clearly than the rate of revision for infection may be 
due to subclinical infections that were not detected and were diagnosed and 
recorded as aseptic loosening or revision for other non-infection causes. This 
was theorized to have been the case in Bohm et al.’s study where ALBC was 
found to reduce the revision rate for aseptic loosening rather than that for 
infection 44, and in Havelin et al.’s study on hip replacements from the Norwegian 
arthroplasty register, where the authors found a trend toward lower revision 
rate due to aseptic loosening in the hip replacements performed using ALBC 
cement compared to those performed using plain 53.  
 
Several patient characteristics, comorbidities, hospital- and surgeon-related 
characteristics have been identified in previous arthroplasty registry-based 
studies as risk factors for developing prosthetic infection after primary TKR. 
These risk factors are: male sex 3,13,52,54, background of diabetes mellitus 52,55, 
primary TKR indication being rheumatoid arthritis 13,56, osteonecrosis 52 or post-
traumatic arthritis 13,52, high body mass index (BMI) 13,51,52,54, increased ASA 
score 3,52,57, high volume hospitals 52,58, quadriceps release exposure 52, 
constrained and hinged knee prostheses 13,  and long operative time 3,52,57.  
The use of ALBC has been shown to be effective at reducing the rate of infection 
following primary TKR performed in diabetic patients 40, in patients whose 
indication for TKR was rheumatoid arthritis 38, and where the primary TKR was 
performed without “clean-air” measures 35,37. 
 
One of the concerns regarding the use of ALBC for infection prophylaxis in 
primary joint arthroplasty is the potential for the ALBC to develop resistant 
organisms that may further complicate infection management should the 
implant become infected 4,20-23; or complicate the reliability of joint fluid and 
tissue cultures during revision surgery 59,60. However, in a study by Hansen et al. 
of primary TKAs and THAs performed using ALBC versus plain cement in the 
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United States, the authors found no change in the patterns of the infecting 
organisms, and no notable increase in the percentage resistance of the organisms 
found at revision surgery 61. They concluded that the routine prophylactic use of 
ALBC did not lead to a change in the profile of the infecting pathogen and did not 
lead to increased resistance of the infecting organisms. Tyas et al. studied the 
rate of deep surgical site infection in hip hemiarthroplasty performed using high-
dose dual-antibiotic cement and those performed using low-dose single-
antibiotic cement and while they found a significantly lower rate of infection in 
patients who received the high-dose dual-antibiotic cement, they too found no 
increase in the cases of bacterial resistance to antibiotics in the high-dose dual-
antibiotic cement group 24.  
 
Another concern is that adding antibiotics to bone cement can adversely affect 
its mechanical properties 16-19. However, none of the available arthroplasty 
registry-based studies found evidence of adverse effect of ALBC on the revision 
rate for non-infective causes. In contrast, Bohm et al. found that ALBC actually 
improved the revision rate for aseptic loosening in primary TKAs 44; and Havelin 
et al. found a trend toward higher revision rate for aseptic loosening in the hip 
replacements performed using plain cement rather than those performed using 
ALBC 53.  We accept that these studies report short-term results and did not 
assess the longer-term effect.  Several studies have also reported incidents of 
bone cellular 25,26 and renal toxicity 27-29 with ALBC. 
 
A recent cost-effectiveness analysis estimated that a reduction of TKR infection 
rate by at least 1.2% as a result of ALBC is required to recover the cost and 
therefore justify of the routine use of ALBC in TKA 15.   In this current study of 
NJR data there was an overall reduction in revision risk at 10 years of 0.87%.  
The NJR annual reports states that 75% of patients with TKR are alive at 10 
years following surgery.62  It is therefore entirely feasible that risk reduction 




After adjusting for a range of variables, ALBC was associated with a 19% lower 
risk of revision.  Using ALBC does not increase mid-term implant failure rates.  
Surgeons using plain cement for primary TKRs should consider changing to 
ALBC in order to reduce overall revision risk. 
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Figure 2:Distribution of number of patients after deleting missing data (BMI) 
 
 
BMI – body mass index, ALBC – antibiotic loaded bone cement 
 
Table 1: Characteristics of patients in the dataset 
 
Variable  
All data  
(n=731214) 
Data with BMI 
(n=432003) 
Age, mean (sd)  70.2  (9.3) 70.1  (9.3) 




422218  (57.7) 
308996  (42.3) 
248343  (57.5) 
183660  (42.5) 








80642  (11.0) 
530146  (72.5) 
117837  (16.1) 
2484  (0.3) 
105  (0.0) 
42763  (9.9) 
316678  (73.3) 
71268  (16.5) 
1274  (0.3) 





710844  (97.2) 
20369  (2.8) 
421485  (97.6) 
10518  (2.4) 
Primary Lead, n Number 5773 4987 
Primary Consultant Number 2984 2618 







580287  (79.4) 
53854  (7.4) 
69290  (9.5) 
27783  (3.8) 
348213  (80.6) 
28823  (6.7) 
39446  (9.1) 
15521  (3.6) 
Approach Medial parapatellar 
Other 
681314 (93.2) 
49900  (6.82) 
403496 (93.4) 
28507  (6.6) 
Cement type ALBC  
Plain 
715919 (97.9) 
15295  (2.1) 
426670 (98.8) 






693867  (94.9) 
32959  (4.5) 
4388  (0.6) 
411335  (95.2) 
19282  (4.5) 







36999  (5.1) 
91987  (12.6) 
359414 (83.2) 
18992  (4.4) 






446666  (61.1) 
192473  (26.3) 
92075  (12.6) 
269029  (62.3) 
109330  (25.3) 







262478  (60.8) 





687661  (94.0) 
43553  (6.0) 
410771  (95.1) 





46392  (6.3) 
684822  (93.7) 
19478  (4.5) 
412525  (95.5) 





229473  (31.4) 
501741  (68.6) 
131163  (30.4) 





639477  (87.5) 
91737  (12.6) 
384243  (88.9) 





679648  (93.0) 
51566  (7.1) 
392831  (90.9) 
39172  (9.1) 
Commented [SJ15]: James suggested separate columns for 
plain and ALBC 
Adetatyo – can this be done? 
Variable  
All data  
(n=731214) 






695711  (96.0) 
28878  (4.0) 
408698  (94.6) 





723337  (98.9) 
7877  (1.1) 
428006  (99.1) 





724024  (99.0) 
7190  (1.0) 
427427  (98.9) 





681637  (93.3) 
48684  (6.7) 
397514  (92.0) 






13391  (1.8) 
81514  (11.2) 
636309 (87.2) 
6741  (1.6) 
31118  (7.2) 
394144  (91.2) 
Revisions:    
Indication  Aseptic 
Infection 
9845  (73.5) 
3546  (26.5) 
4884  (72.5) 




Single stage revision 
Revision 1st stage 
Revision 2nd stage 
Conversion 
Amputation 
10246  (76.5) 
2239  (16.7) 
873  (6.4) 
26  (0.2) 
7  (0.1) 
5202  (77.2) 
1174  (17.4) 
353  (5.2) 
11  (0.2) 
1  (0.0) 
BMI  – body mass index 
ASA  – American Society of Anesthesiologists  
SAS  – Staff/Associate Specialist 
ST  – Specialty trainee 
ALBC  – Antibiotic loaded bone cement 
VTE  – Venous thromboembolic 


















Figure 3: Survival curves for each revision category, stratified by cement type 
(n=revision events) . 
 




Figure 4: Line charts describing the association between the hazards of revision 
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Table 2: Simple (unadjusted) analyses for the three categories of revision 
groups using the entire dataset. (BMI was not included in these analyses) 
 Revision for infection Aseptic revision All cause revision 






















































































































































































































































































































Type of chemical VTE 
thromboprophylaxis: 














































































 Revision for infection Aseptic revision All cause revision 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Yes 1.02 (0.75,1.39) 0.883 0.80 (0.66,0.99) 0.037 0.86 (0.73,1.02) 0.085 










































CI  – Confidence intervals  
HR  – Hazard ratio 
ASA  – American Society of Anesthesiologists  
VTE  – Venous thromboembolic 
LMWH  – Low molecular weight heparin 
 
 
Table 3: Multivariable (adjusted) analysis of association between revision rate 
(all cause) and the use ALBC, adjusting for other factors (including year of 
operation) using un-stratified and stratified Cox proportional hazard models. 
(Only variable categories with significant influences included here. BMI was not 




 UNSTRATIFIED ANALYSIS  STRATIFIED ANALYSIS  
 ALL PATIENTS EXCLUDING DEAD  ALL PATIENTS  EXCLUDING DEAD 










































































































































































































































































































CI  – Confidence intervals  
HR  – Hazard ratio 
ASA  – American Society of Anesthesiologists  
Figure 5: Survival curves stratified by ALBC when the event is due to infection (left 
panel), to no-infection (middle panel) and when we combine the infection and no-
infection.  N represents the number of events, particularly after two years. 
 
 





























































































Table 4: Simple (unadjusted) analyses for the three categories of revision groups 
using the dataset where BMI data was available 
 Revision for infection Aseptic revision All cause revision 























































































































































































































































































































Type of chemical VTE 
thromboprophylaxis: 
































































Warfarin       
 Revision for infection Aseptic revision All cause revision 
































































CI  – Confidence intervals  
HR  – Hazard ratio 
ASA  – American Society of Anesthesiologists 
BMI – Body mass index  
VTE  – Venous thromboembolic 
LMWH  – Low molecular weight heparin 
 
Table 5: Multivariable Multivariable (adjusted) analysis of association 
between revision rate (all cause) and the use ALBC, adjusting for other 
factors (including year of operation) using un-stratified and stratified 
Cox proportional hazard models. (Only variable categories with 




UNSTRATIFIED ANALYSIS  STRATIFIED ANALYSIS  
 ALL PATIENTS  EXCLUDING DEAD  ALL PATIENTS  EXCLUDING DEAD 










































































































































































































































































































CI  – Confidence intervals  
HR  – Hazard ratio 
BMI – Body mass index 
ASA  – American Society of Anesthesiologists 
 
 
 
 
 
